Recent data support the hypothesis that combining lapatinib and trastuzumab with taxane chemotherapy may offer added clinical benefit to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). This study examined the safety of the triplet combination in first-line HER2-positive MBC.
Pharmacology, Toxicology and Pharmaceutical Science
4
8%
Nursing and Health Professions
4
8%
Psychology
3
6%
Agricultural and Biological Sciences
2
4%
Other
6
13%
Unknown
15
31%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 May 2013.
All research outputs
#22,470,839
of 34,545,128 outputs
Outputs from Oncologist
#3,545
of 4,900 outputs
Outputs of similar age
#158,263
of 243,051 outputs
Outputs of similar age from Oncologist
#32
of 51 outputs
Altmetric has tracked 34,545,128 research outputs across all sources so far. This one is in the 33rd percentile – i.e., 33% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,900 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.8. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,051 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
